Introduction {#s1}
============

Multiple sclerosis (MS) is a chronic inflammatory disease which affects the central nervous system and it is characterized by myelin destruction, axonal degeneration and progressive neurological dysfunction. MS shows a complex etiology, which comprises the interplay of genetic and environmental factors. A clear and well established influence of the Human Leukocyte Antigen (HLA) allele *DRB1\*15:01* has been shown in almost all the populations studied, pointing to this allele as the main risk factor contributing to disease susceptibility. However, it is known that other HLA genetic variants influence disease development, but the additional genetic contribution of this region is far to be understood. Although the special characteristics of this region and the very probable existence of epistatic interactions between different HLA risk alleles [@pone.0031018-Lincoln1], [@pone.0031018-Dyment1] hampers the study of this region, small steps can be taken trying to elucidate this problem. A relevant issue to deal with is the one concerning *DRB1\*03:01*. This allele has been consistently associated with high MS risk in Sardinia [@pone.0031018-Marrosu1], [@pone.0031018-Marrosu2], but heterogeneous data exist regarding the effect of *DRB1\*03:01* in other populations [@pone.0031018-Lincoln1], [@pone.0031018-Marrosu1], [@pone.0031018-Masterman1], [@pone.0031018-Benedek1], [@pone.0031018-Ramagopalan1], [@pone.0031018-Barcellos1].

HLA peculiarities include the existence of specific allele combinations over large regions which have been conserved across generations and conform the so-called ancestral haplotypes (AH). The *DRB1\*03:01* allele is present in two AH: 18.2 and 8.1, i.e., it can be found in two different haplo-specific contexts. Besides, this allele can be found within non-specific allelic combinations, including partially-conserved 18.2 and 8.1 AH fragments, thereafter called non-conserved haplotypes. The frequency of those *DRB1\*03:01*-containing haplotypes varies greatly depending on the geographical location. Thus, in populations of Northern Europe *DRB1\*03:01* appears preferentially in the AH 8.1, but it does in the AH 18.2 in Sardinia. According to this, differences in the MS risk conferred by those haplotypes could be underlying the heterogeneity observed in the previously published studies focused in the *DRB1\*03:01* allele.

In the Spanish population, our research group described an association between MS susceptibility and one polymorphism located in the promoter of the tumor necrosis factor-alpha (*TNF*) gene, rs1800750 (*TNF* -376) [@pone.0031018-FernandezArquero1], [@pone.0031018-Martinez1]. Later, association with *TNF* rs1800750 was also found in a subgroup of Spanish MS patients characterized by the presence of oligoclonal IgM bands against myelin lipids (OCMB) restricted to cerebrospinal fluid (CSF) [@pone.0031018-Villar1], which has been described as conditioning an aggressive MS course. In both cases, the susceptibility allele was rs1800750_A, which is almost exclusively present on the AH 18.2. Of note, in Spain, like in other populations of South Europe, the three subsets of *DRB1\*03:01*-bearing haplotypes (AH 18.2, AH 8.1 and non-conserved ones) appear approximately at a similar frequency. This situation enables us to investigate whether those subsets contribute in a similar manner to MS susceptibility.

In the present work, we aimed at studying the role of *DRB1\*03:01* in relation to MS risk and production of oligoclonal IgM against myelin lipids, with special attention to the putatively different contribution of the different haplotypes bearing that allele.

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

This study was approved by the ethical committees of the participant hospitals (Comité Ético de Investigación Clínica (CEIC) del Hospital Clínico San Carlos, CEIC del Hospital Ramón y Cajal and CEIC del Hospital Universitario Carlos Haya). Samples were obtained after obtaining written informed consent.

Subjects {#s2b}
--------

We studied 929 MS patients diagnosed following the Poser criteria [@pone.0031018-Poser1] and 624 ethnically matched individuals without autoimmune diseases as controls. All individuals were Spanish of Caucasian ancestry. Samples were consecutively recruited at both Hospital Clínico San Carlos (Madrid) and Hospital Universitario Carlos Haya (Málaga). Population stratification is not present in our samples, since reduced genomic control inflation factor was observed after genotyping more than 200,000 SNPs.

To study the influence of *DRB1\*03:01* on the presence of OCMB, we studied 139 independent MS patients recruited at the Hospital Ramón y Cajal (Madrid). All these patients showed a relapsing-remitting disease; a total of 58 patients showed OCMB in CSF (M+ group) and 81 lacked them (M− group).

HLA Genotyping {#s2c}
--------------

DNA was extracted from fresh peripheral blood leukocytes by a "salting out" procedure. *HLA-B*, -*DRB1* and -*DQB1* were typed by polymerase chain reaction-sequence-specific oligonucleotide (PCR-SSO) following manufacturer recommendations (Tepnel Lifecodes Corp., Stamford, CT, USA). The presence of the *DRB1\*15:01* allele was also tested by TaqMan technology using the highly correlated SNP rs3135388 (Applied Biosystems Inc., Foster City, CA, USA).

AH 18.2 and 8.1 were assessed by genotyping of *HLA-B*, -*DRB1* and -*DQB1*. Additionally, the *TNF* singe nucleotide polymorphisms −308 (rs1800629) and −376 (rs1800750) and the microsatellites *TNFa* and *TNFb* were also ascertained. *TNF* polymorphisms were typed as previously described [@pone.0031018-FernandezArquero1], [@pone.0031018-Nedospasov1].

IgM detection {#s2d}
-------------

Detection of the lipid-specific oligoclonal IgM bands was performed by isoelectric focusing and immunoblotting as previously described [@pone.0031018-Villar2].

Statistical analysis {#s2e}
--------------------

HLA haplotypes were estimated using the EM (Expectation-Maximization) algorithm implemented in the Arlequin software.

Comparisons between groups were performed with the chi-square test or the Fisher\'s exact test when proper (expected values below 5) using the statistical package EpiInfo v5.00 (CDC, Atlanta, USA). Heterogeneity between groups was evaluated with Review Manager (RevMan) 5.0 software (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008).

Results {#s3}
=======

No heterogeneity was observed between samples collected in Madrid and Málaga, therefore, pooled data are presented.

The frequency of the different *DRB1\*03:01*-containing haplotypes in MS patients and in controls is shown in [Table 1](#pone-0031018-t001){ref-type="table"}. Patients were stratified according to the presence/absence of the *DRB1\*15:01* allele risk, but no differences were found between those two MS groups when *DRB1\*03:01* data were analysed; therefore, all MS patients were combined (column "total" of [Table 1](#pone-0031018-t001){ref-type="table"}) for case-control comparisons.

10.1371/journal.pone.0031018.t001

###### Frequency of the different *DRB1\*03:01*-containing haplotypes in *DRB1\*15:01* positive (+) and negative (−) multiple sclerosis (MS) patients and in controls; and case-control study for the total MS patients.

![](pone.0031018.t001){#pone-0031018-t001-1}

                              MS PATIENTS   CONTROLS        MS PATIENTS vs. CONTROLS                                                                                         
  -------------------------- ------------- ---------- ------------------------------------- ------ -------------------------------------- ------ ------ ------ ------------- -------------------
  ***DRB1\*03:01***                                                                                                                                                          
  **All**                         233         19.5                     57                    17.2                   290                    19.0   167    13.4   7.1\*10^−5^   1.52 (1.23--1.88)
  **AH 18.2**                     88          7.4                      24                    7.2                    112                    7.3     49    3.9    1.3\*10^−4^   1.94 (1.36--2.78)
  **AH 8.1**                      60          5.03                     17                    5.1                     77                    5.05    53    4.3       0.23       1.25 (0.86--1.81)
  **Non-conserved**               85          7.1                      16                    4.8                    101                    6.6     65    5.2       0.072      1.34 (0.96--1.87)
  **AH 8.1+Non-conserved**        145         12.1                     33                    9.9                    178                    11.7   118    9.5       0.027      1.32 (1.02--1.70)
  **TOTAL NUMBER**               1194                  332[1](#nt103){ref-type="table-fn"}          1526[1](#nt103){ref-type="table-fn"}          1248                       

\% are referred to the total number of haplotypes analysed in each group (last row).

AH 18.2 includes haplotypes carrying *DRB1\*03:01*, *DQB1\*02:01*, *TNF -376A*, *TNF a1b5* and *B\*18*. AH 8.1 includes haplotypes carrying *DRB1\*03:01*, *DQB1\*02:01*, *TNF -308A*, *TNF a2b3* and *B\*8*. Haplotypes with all the remaining allelic combinations in those loci or markers are included as "non-conserved" haplotypes.

Excluding the *HLA-DRB1\*15:01*-containing haplotypes.

First, we investigated the possible role of *DRB1\*03:01* in MS susceptibility and we observed a highly significant effect: OR = 1.52, 95% CI 1.23--1.88, p = 7.1\*10^−5^. Since AH 18.2 and AH 8.1 appear at a similar frequency in the Spanish controls (around 30% of all *DRB1\*03:01*), we could evaluate the possible different contribution of those two haplotypes in disease risk. We started with AH 18.2 analysis, which showed a significant association and higher risk than when considering all *DRB1\*03:01*-bearing haplotypes: OR = 1.94, 95% CI 1.36--2.78, p = 1.3\*10^−4^ ([Table 1](#pone-0031018-t001){ref-type="table"}). Due to its key role in MS risk, 18.2 haplotypes were removed from subsequent analysis in order to ascertain a putative effect of other AHs. We examined the influence of AH 8.1, but a significant result was not obtained. Similarly, no association was found when considering the non-conserved *DRB1\*03:01* haplotypes. However, since statistical power limitations could be affecting these results, we combined AH 8.1 and non-conserved *DRB1\*03:01* haplotypes data (given their lack of heterogeneity: p = 0.76; I^2^ = 0%) and then a significant result emerged (p = 0.027, OR = 1.32, 95% CI 1.02--1.70), pointing to a contribution of *DRB1\*03:01* carrying haplotypes others than AH 18.2 to MS risk, as seems to be deduced from the existing literature. To obtain a more accurate estimation of the specific effect caused by AH 18.2, we excluded AH 8.1 and non-conserved haplotypes from the initial analysis and we obtained an OR = 2.00, 95% CI 1.40--2.87 (p = 6.4\*10^−5^). Of note, heterogeneity was detected between AH 18.2 and the remaining *DRB1\*03:01* haplotypes: p = 0.05, I^2^ = 74%, supporting the mentioned stronger effect on MS risk of this AH.

Next, we studied the involvement of *DRB1\*03:01* in the presence of OCMB in MS patients ([Table 2](#pone-0031018-t002){ref-type="table"}). No differences were observed between patients stratified by the presence (M+ group)/absence (M− group) of OCMB when considering all *DRB1\*03:01* haplotypes. However, a different scenario emerged after individual analysis of the different *DRB1\*03:01* haplotypes. The previously observed effect for AH 18.2 was exclusively present when studying M+ patients (p = 0.0088 M+ vs. M−; p = 0.0055 M+ vs. controls). No differences seemed to exist between M+ and M− for *DRB1\*03:01* haplotypes others than the AH 18.2.

10.1371/journal.pone.0031018.t002

###### Frequency of the different *DRB1\*03:01*-containing haplotypes in multiple sclerosis (MS) patients stratified by the presence/abscence of oligoclonal IgM against myelin lipids (M+/M−) and in controls; and comparisons between groups.

![](pone.0031018.t002){#pone-0031018-t002-2}

                               MS PATIENTS   CONTROLS   M+ vs. M−   M+ vs. Controls   M− vs. Controls                                                                  
  --------------------------- ------------- ---------- ----------- ----------------- ----------------- ------ ---------------------------- --------------------------- -------------------------
  ***DRB1\*03:01***                                                                                                                                                    
  **All**                          19          20.4        20            15.2               167         13.4    0.30, 1.44 (0.68--3.04)     0.058, 1.66 (0.94--2.90)    0.57, 1.16 (0.68--1.96)
  **AH 18.2**                      10          10.8         3             2.3               49          3.9    0.0088, 5.05 (1.23--29.24)   0.0055, 2.98 (1.36--6.39)   0.27, 0.59 (0.12--1.88)
  **AH 8.1**                        2          2.2          6             4.5               53          4.3     0.48, 0.50 (0.05--2.93)      0.55, 0.54 (0.06--2.17)    0.84, 1.09 (0.38--2.62)
  **Non-conserved**                 7          7.5         11             8.3               65          5.2     0.94, 0.96 (0.32--2.84)      0.19, 1.57 (0.59--3.60)    0.15, 1.63 (0.79--3.30)
  **AH 8.1+ Non-conserved**         9          9.7         17            12.9               118         9.5     0.61, 0.80 (0.31--2.03)      0.77, 1.11 (0.51--2.37)    0.23, 1.39 (0.78--2.46)
  **TOTAL NUMBER**                 93                      132                             1248                                                                        

\% are referred to the total number of haplotypes analysed in each group (last row).

AH 18.2 includes haplotypes carrying *DRB1\*03:01*, *DQB1\*02:01*, *TNF -376A*, *TNF a1b5* and *B\*18*. AH 8.1 includes haplotypes carrying *DRB1\*03:01*, *DQB1\*02:01*, *TNF -308A*, *TNF a2b3* and *B\*8*. Haplotypes with all the remaining allelic combinations in those loci or markers are included as "non-conserved" haplotypes.

*HLA-DRB1\*15:01*-containing haplotypes in MS patients were removed from the analysis.

Since the two groups of MS patients studied ([Table 1](#pone-0031018-t001){ref-type="table"} and [Table 2](#pone-0031018-t002){ref-type="table"}) constitute independent samples, we combined their data to increase statistical power and a significant association was observed when considering the *DRB1\*03:01* non-conserved haplotypes: p = 0.037, OR = 1.39, 95% CI 1.01--1.93.

We also evaluated the effect of the *DRB1\*15:01* allele in M+ and M− patients. A similar risk was observed in both groups of patients, also similar to the risk observed when considering the overall MS patients: OR = 2.56, 95% CI 1.99--3.29 (allelic risk). This effect is similar to the one caused by the AH 18.2 in M+ patients (heterogeneity: p = 0.69; I^2^ = 0%) and significantly higher to the risk conferred by the non-conserved *DRB1\*03:01* haplotypes (heterogeneity: p = 0.003; I^2^ = 89%).

Discussion {#s4}
==========

Last years have witnessed an increasing number of genetic regions involved in MS susceptibility; however, the strongest association signals with disease risk remain in the long-known HLA region. Nevertheless, except for the well-established effect of *HLA-DRB1\*15:01*, genetic influence at this region remains elusive.

We studied the risk conferred by the different *DRB1\*03:01*-containing haplotypes (AH 18.2, AH 8.1 and non-conserved haplotypes) in relation to MS susceptibility and, specifically, to the presence of intrathecal IgM against myelin lipids restricted to CSF in MS patients. Our results indicate that patients bearing the AH 18.2 show an increased risk to produce intrathecal IgM (OR = 2.98 95% CI 1.36--6.39) and this effect seems to be independent of the presence of *HLA-DRB1\*15:01*. The strong effect caused by this haplotype, together with the considerable percentage of M+ individuals among MS patients (around 40%), makes that a susceptibility signal emerges also when considering the overall MS patients independently of the presence/absence of OCMB, although, obviously, causing an apparently lower risk.

This finding could explain the heterogeneous results regarding *HLA-DRB1\*03* previously published. The percentage of AH 18.2 from the total *HLA-DRB1\*03* and the percentage of M+ individuals from the total MS patients will determine obtaining a significant result. Moreover, the situation is probably more complicated. Although statistical power limitations preclude a conclusive interpretation of data regarding *DRB1\*03* haplotypes others than 18.2, it seems that at least the non-conserved ones influence disease development, although with a lower risk.

A different disease risk caused by the diverse *DRB1\*03*-bearing haplotypes has also been described in type 1 diabetes (T1D). Baschal et al. reported the highest risk for the AH 18.2 and the lowest risk for AH 8.1 [@pone.0031018-Baschal1]. More powered studies are required to establish whether the AH 8.1 contributes to MS development. Our data discard a strong effect for AH 8.1, as the one observed for AH 18.2, and, consequently, our sample size could not be enough to obtain a significant result, although it might exist. The reported association between *DRB1\*03:01* and MS risk in some Northern-European populations [@pone.0031018-Masterman1], where the most common *DRB1\*03:01* haplotype is the AH 8.1, suggests that it could be contributing to disease risk.

The previously described association of MS and OCMB with *TNF* -376A seems to be due to the presence of this allele on the AH 18.2 and therefore, to the linkage disequilibrium with the causal variant/s present on that haplotype.

The association of AH18.2 and intrathecal anti-lipid IgM synthesis could have important clinical implications. The presence of those antibodies has been related to development of an aggressive MS [@pone.0031018-Villar2], [@pone.0031018-Thangarajh1], [@pone.0031018-Perini1] and it has been described that those patients could benefit of an early immunomodulatory treatment [@pone.0031018-GarciaBarragan1]. Moreover, a better response to treatment with interferon-beta has been described for patients lacking OCMB [@pone.0031018-Bosca1]. Therefore, MS patients carrying the AH18.2 deserve special attention. It must be underlined that only 4% of patients with that haplotype do not have intrathecal IgM. However, further research is needed since AH 18.2 appears in 12% of M+ individuals and additional factors must therefore contribute to IgM production.

MS is characterized by an extensive heterogeneity in terms of clinical features, pathogenesis or responsiveness to treatments. The mechanism underlying those differences is still uncovered, but a genetic contribution must exist. Therefore, the analysis of the overall MS patients can miss genetic variants relevant for certain groups, as it is proved in our work. On the contrary, the study of well-characterized subgroups seems to be a good strategy to further increase the number of genes involved in MS susceptibility, contributing to elucidate part of the "missing heritability" [@pone.0031018-Manolio1]. Despite the great advances in the genetics of MS, more than 50% of the disease heritability remains unsolved. Our results show an increase of the odds ratio as we define the best marker of the causal variant/s and the specific affected subgroup. Thus, from an initial OR = 1.52 conferred by *DRB1\*03:01*, we moved to OR = 1.94 caused by the specific AH 18.2 to MS overall and to OR = 2.98 when we consider specifically M+ patients. Note that this effect is similar to the one caused by *DRB1\*15:01*, the main risk factor to MS susceptibility. A parallel situation is expected for genetic variants affecting only subgroups of patients. According to our data, promising results can be expected from studying more homogeneous groups of MS patients.
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